New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
17:28 EDTTGEN
theflyonthewall.com: Targeted Genetics regains Nasdaq compliance
Targeted Genetics Corporation announced that, on September 28, the Nasdaq granted the company's request to remain listed on The Nasdaq Capital Market. The company's continued listing is subject to regaining compliance with the Nasdaq listing requirements by evidencing shareholders' equity of $2.5M on or before January 19, 2010 and achieving a closing bid price of $1.00 or more for a minimum of 10 consecutive trading days on or before February 8, 2010, as well as maintaining compliance with all other requirements for continued listing on the Nasdaq Capital Market. In addition, the company must inform the Nasdaq panel if the company determines not to pursue a reverse stock split as a means, if necessary, to enable the company to regain compliance with the $1.00 share price requirement. If the company does not satisfy the foregoing conditions, the Nasdaq panel will issue a final determination to delist the company's common stock and will suspend trading of the company's shares effective on the second business day after the date of the Panel's final determination. :theflyonthewall.com



News For TGEN From The Last 14 Days
Check below for free stories on TGEN the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2010
06:22 EDTTGEN
theflyonthewall.com: Targeted Genetics gives FY10 projections on cash use
Targeted Genetics estimates it finished 2009 with cash and cash equivalents of approximately $4.9M. The company intends over the next year to utilize its resources to support continued efforts to monetize certain assets, to realize value from milestone and royalty licensing relationships, and to support product development programs currently underway with commercial and academic partners. Accordingly, based on its current business plans the company expects its net use of cash during 2010 will not exceed $2M. The company’s use of cash in 2010 could be greater if the company decides to increase spending during the year on new or current programs or other operating activities. :theflyonthewall.com
06:19 EDTTGEN
theflyonthewall.com: Targeted Genetics receives payment from Amsterdam Molecular Therapeutics
Targeted Genetics reported that it received a $750,000 milestone payment from Amsterdam Molecular Therapeutics B.V. ,“AMT”. This milestone payment was received pursuant to a patent license agreement between the Company and AMT and was triggered by AMT’s filing for marketing approval of Glybera, a product candidate for the treatment of lipoprotein lipase deficient patients. AMT announced the regulatory filing with the European Medicines Agency on January 11, 2010. :theflyonthewall.com
06:10 EDTTGEN
theflyonthewall.com: Targeted Genetics receives milestone payments from Genzyme

Subscribe for More Information :theflyonthewall.com